Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report

被引:0
|
作者
McConnell, Ashlyn [1 ]
Stoneman, Tyler [2 ]
Hewlett, Stanley [1 ]
机构
[1] Princeton Baptist Med Ctr, Dept Surg, Birmingham, AL 35211 USA
[2] Edward Via Coll Osteopath Med, Spartanburg, SC 29303 USA
来源
JOURNAL OF SURGICAL CASE REPORTS | 2023年 / 2023卷 / 10期
关键词
pancreatic cancer; CA; 19-9; jaundice; tumor markers;
D O I
10.1093/jscr/rjad550
中图分类号
R61 [外科手术学];
学科分类号
摘要
Carbohydrate antigen (CA 19-9) is the most validated marker for both sensitivity and specificity of pancreatic adenocarcinoma used to aid diagnosis of symptomatic patients as well as to evaluate the progression or treatment of disease. Though higher levels of CA 19-9 tend to correlate with neoplastic disease, elevated levels are also often seen in patients with benign gastrointestinal diseases, such as obstructive jaundice and pancreatitis. We present a case of a 74-year-old male who was admitted for abdominal pain and worsening jaundice who was diagnosed with extensive pancreatic necrosis and an underlying invasive pancreatic adenocarcinoma whose serum level of CA 19-9 was found to be extraordinarily high.
引用
收藏
页数:2
相关论文
共 50 条
  • [41] CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma
    Hayman, Amanda V.
    Stocker, Susan J.
    Baker, Marshall S.
    Bentrem, David J.
    Prinz, Richard A.
    Marsh, Robert de W.
    Talamonti, Mark S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (06): : 550 - 554
  • [42] CA 19-9 in the differential diagnosis of pancreatic lesions
    Stintzing, S.
    Herold, C.
    Hahn, E. G.
    Boxberger, F.
    INTERNIST, 2008, 49 (02): : 225 - 227
  • [43] CA 19-9: Not a magic marker for pancreatic cancer
    Daram, Sumanth R.
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (03) : 205 - 205
  • [44] Exploiting the relevance of CA 19-9 in pancreatic cancer
    Salleh, Syaza
    Thyagarajan, Anita
    Sahu, Ravi P.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6
  • [45] Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano, Gianpaolo
    Di Carlo, Valerio
    LANCET ONCOLOGY, 2008, 9 (02): : 89 - 91
  • [46] CA 19-9 and Lewis Antigens in Pancreatic Cancer
    Atkins, Carl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2572 - 2573
  • [47] CA-19-9 AND PANCREATIC ADENOCARCINOMA
    SAFI, F
    BEGER, HG
    BITTNER, R
    BUCHLER, M
    KRAUTZBERGER, W
    CANCER, 1986, 57 (04) : 779 - 783
  • [48] THE CORRELATION OF ADJUSTED SERUM CARBOYDRATE ANTIGEN 19-9 WITH HISTOLOGICAL GRADE IN PANCREATIC ADENOCARCINOMA
    Ortiz-Gonzalez, J.
    Alvarez-Aguila, N. P.
    Medina-Castro, J. M.
    Recinos-Money, E. A.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3587 - 3588
  • [49] VALUES OF CA 19-9 IN THE SERUM, PURE PANCREATIC-JUICE, AND ASPIRATED PANCREATIC MATERIAL IN THE DIAGNOSIS OF MALIGNANT PANCREATIC TUMOR
    TATSUTA, M
    YAMAMURA, H
    IISHI, H
    ICHII, M
    NOGUCHI, S
    YAMAMOTO, R
    OKUDA, S
    CANCER, 1985, 56 (11) : 2669 - 2673
  • [50] Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9
    Lundin, J
    Roberts, PJ
    Kuusela, P
    Haglund, C
    ANTICANCER RESEARCH, 1995, 15 (5B) : 2181 - 2186